Clin Asst Prof Lai Geet Yi Gillianne

Dr Gillianne Lai is a Consultant in Medical Oncology at the National Cancer Centre Singapore, sub-specialising in thoracic, head and neck and genitourinary cancers. She obtained her undergraduate degree from the Yong Loo Lin School of Medicine, National University of Singapore and is a member of the Royal College of Physicians of the United Kingdom.

She completed her Medical Oncology specialty training at the National Cancer Centre Singapore. She has a strong interest in thoracic oncology and is actively involved in research. She currently leads the Lung Cancer Consortium Singapore (LCCS), and is the Principal Investigator of SOLSTICE, Singapore’s first lung cancer screening study.

• MMed (Internal Medicine) 2015 
• MRCP (UK) 2015 
• MBBS (Singapore) 2012

• Consultant, Division of Medical Oncology, National Cancer Centre Singapore
• International Association for the Study of Lung Cancer (IASLC), Member
• Singapore Society of Oncology (SSO), Member
• Physician Faculty Member, SingHealth Medical Oncology Residency Programme
  
• Clinical Physician Faculty Member, Singhealth Internal Medicine Residency Programme

• SingHealth Publish! Award 2020
• Young Investigator's Travel Award, IASLC 18^th World Conference of Lung Cancer 2017
• Outstanding Resident Award (SingHealth Residency) 2017
• Best Medical Officer Award 2014

• ​Thoracic Oncology

• Lung cancer screening in never smokers. Lai GGY, Tan DSW. Curr Opin Oncol 2025 Jan 1;37(1):95-104. 
• Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer. Tan AC, Lai GGY, Saw SPL, Chua KLM, Takano A, Ong BH, Koh TPT, Jain A, Tan WL, Ng QS, Kanesvaran R, Rajasekaran T, Kalashnikova E, Renner D, Sudhaman S, Malhotra M, Sethi H, Liu MC, Aleshin A, Lim WT, Tan EH, Skanderup AJ, Ang MK, Tan DSW. Cancer. 2024; 130: 1758-1765. 
• Oncogene-driven non-small cell lung cancers in patients with a history of smoking lack smoking-induced mutations. Huang CY, Jiang N, Shen M, Lai GG, Tet al. Cancer Res. 8 Apr 2024. doi: 10.1158/0008-5472.CAN-23-2551. Epub ahead of print. 
• Molecular testing in non-small cell lung cancer: A consensus recommendation. Lai GGY, Cheng XM, Ang YLE et al. Ann Acad Med Singapore. 2023 Jul 28;52(7):364-373. 
• Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor re-sistance. Ma J, Tan SH, Yin DXC, Tran NTA, Tan GS, Lai GGY, Ang MK, Kanesvaran R, Jain A, Ra-jasekaran T, Tan EH, Lim TKH, Tan DS, Lim DW, Ng QS, Tan WL. Translational Lung Cancer Re-search. Apr 2023; 12(4): 742-753. 
• PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer. Saw SPL, Ng WP, Zhou S, Lai GGY, Tan AC, Ang MK, Lim WT, Kanesvaran R, Ng QS, Jain A, Tan WL, Rajasekaran T, Chan JWK, Teh YL, Pang M, Yeo JC, Takano A, Ong BH, Tan EH, Tan SH, Skanderup AJ, Tan DSW. Eur J Cancer. Jan 2023; 178: 139-149. doi: 10.1016/j.ejca.2022.10.012. Epub 2022 Oct 20. PMID: 36436331 
• Dietary factors and the risk of lung cancer by epidermal growth factor receptor mutation status and histological subtypes. Yin X, Lai GGY, Seow A. et al. Front Public Health. 2022; 10: 1-13. https://doi.org/10.3389/fpubh.2022.1079543 • Multidisciplinary lung cancer clinic: An emerging model of care. Saw SPL, Chua KLM, Ong BH, Lim DWT, Lai GGY, Tan DSW, Ang MK. Ann Acad Med Singap. Dec 2022; 51(12): 793-795. doi: 10.47102/annals-acadmedsg.2022295. PMID: 36592148. 
• Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision. Lai GGY, Guo R, Drilon A, Shao Weng Tan D. Cancer Treat Rev. Nov 2022; 110: 102444.
• Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities. Chua KP, Teng YHF, Tan AC, Takano A, Alvarez JJS, Nahar R, Ro-hatgi N, Lai GGY, Aung ZW, Yeong JPS, Lim KH, Naeini MM, Kassam I, Jain A, Tan WL, Gogna A, Too CW, Kanesvaran R, Ng QS, Ang MK, Rajasekaran T, Anantham D, Phua GC, Tan BS, Lee YY, Wang L, Teo ASM, Khng AJ, Lim MJ, Suteja L, Toh CK, Lim WT, Iyer NG, Tam WL, Tan EH, Zhai W, Hillmer AM, Skanderup AJ, Tan DSW. Clinical Cancer Research. Nov 2021; 27(21): 5939-5950. 
• Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. Saw SPL, Zhou S, Chen J, Lai G, et al. JAMA Network Open. Nov 2021; 4(11): 1-14. 
• Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC. Tan AC, Seet AOL, Lai GGY, et al. Journal of Thoracic Oncology. Dec 2020; 15(12): 1928-1934. 
• Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Tan AC, Lai GGY, Tan GS, et al. Lung Cancer. Jan 2020; 139: 207-215. 
• Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer. Lai GGY, Lim TH, Lim J, et al. J Clin Oncol. Apr 2019; 10;37(11): 876-884